Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept versus rituximab retreatment after inadequate response to first rituximab course in active rheumatoid arthritis
2009-009178-28Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in rheumatoid arthritis (RA) comparing Etanercept + methotrexate with Rituximab retreatment + methotrexate (2 arms). Primary endpoint: EULAR responder rate at weeks 12 and 24. Started Mar 2009; status: active.
02
Drugs
etanerceptrituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-009178-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009178-28.